Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue SUPPL. 1, 2002, Pages 9-12

  Wilde, Jonathan T ^a,b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

aPCC; Autoplex T; Bypassing agent; FEIBA ; Inhibitor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; PROTHROMBIN COMPLEX; ALLOANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX CONCENTRATES;

BLEEDING; CONFERENCE PAPER; HEMOPHILIA; HUMAN; PRIORITY JOURNAL; BLOOD; CHEMISTRY; EVIDENCE BASED MEDICINE; HEMOPHILIA A; IMMUNOLOGY; REVIEW;

AUTOANTIBODIES; BLOOD COAGULATION FACTORS; EVIDENCE-BASED MEDICINE; HEMOPHILIA A; HEMORRHAGE; HUMANS; ISOANTIBODIES;

EID: 0347552464     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057293     Document Type: Conference Paper

References (15)

1. Turecek PL, Varadi K, Gritsch H, Schwarz HP: Activated prothrombin complex concentrates induce hemostasis by a balanced effect at multiple sites of the coagulation pathway. Haemophilia 1998;4:168 (abstract).
2. Lundblad RL, Bergstrom J, De Vreker R, Bray G, Gomperts E, Baker D, Kingdon HS, Mann KG, Hartshorn J, Jenny RJ: Measurement of active coagulation factors in Autoplex®-T with colorimetric active site-specific assay technology. Thromb Haemost 1998;80:811-815.
3. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Houwelingen H, van Asten P, Sixma JJ: The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305:717-721.
4. Hilgartner MW, Knatterud GL: The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitors. Blood 1983;61:36-40.
5. Hilgartner M, Aledort L, Andes A, Gill J: Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA study group. Transfusion 1990;30:626-630.
6. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P: Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997;77:1113-1119.
7. Kurczynski EM, Penner JA: Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974;291:164-167.
8. Abildgaard CF, Penner JA, Watson-Williams EJ: Anti-inhibitor Coagulant Complex (Autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood 1980;56:978-984.
9. Lusher JM, Blatt PM, Penner JA, Alcdort LM, Levine PH, White GC, Warrier AI, Whitehurst DA: Autoplex versus proplex: A controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983;62:1135-1138.
10. Kantrowitz JL, Lee ML, McClure DA, Kingdon HS, Thomas WR: Early experience with the use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII. Clin Therapeut 1987;9:405-419.
11. Penner JA: Management of haemophilia in patients with high-titre inhibitors: Focus on the evolution of activated prothrombin complex concentrate AUTOPLEX T. Haemophilia 1999;5(suppl3):1-9.
12. Hanna WT, Madigan RR, Miles MA, Lange RD: Activated factor IX complex in treatment of surgical cases of hemophilia A with inhibitors. Thromb Haemost 1981;46:638-641.
13. Horwith G, Revie DR: Efficacy of viral clearance methods used in the manufacture of activated prothrombin complex concentrates: Focus on AUTOPLEX T. Haemophilia 1999; 5(suppl 3):19-23.
14. Hay CRM, Baglin TP, Collins PW, Hill FGH, Keeling DM: The diagnosis and management of factor VIII and factor IX inhibitors: A guideline from the UK haemophilia center Doctors' organization (UKHCDO). Br J Haematol 2000;111:78-90.
15. Green D: Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999;5(suppl 3):11-17.